These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 36389677

  • 1. A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies.
    Takashima E, Nagaoka H, Correia R, Alves PM, Roldão A, Christensen D, Guderian JA, Fukushima A, Viebig NK, Depraetere H, Tsuboi T.
    Front Immunol; 2022; 13():1002430. PubMed ID: 36389677
    [Abstract] [Full Text] [Related]

  • 2. Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells.
    Correia R, Fernandes B, Castro R, Nagaoka H, Takashima E, Tsuboi T, Fukushima A, Viebig NK, Depraetere H, Alves PM, Roldão A.
    Front Bioeng Biotechnol; 2022; 10():908509. PubMed ID: 35845392
    [Abstract] [Full Text] [Related]

  • 3. The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals.
    Tamborrini M, Schäfer A, Hauser J, Zou L, Paris DH, Pluschke G.
    Malar J; 2023 Jul 15; 22(1):210. PubMed ID: 37454145
    [Abstract] [Full Text] [Related]

  • 4. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH, Arisue N, Ito D, Hasegawa T, Palacpac NMQ, Egwang TG, Horii T, Takashima E, Tsuboi T.
    Vaccine; 2016 Nov 04; 34(46):5612-5622. PubMed ID: 27692771
    [Abstract] [Full Text] [Related]

  • 5. Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA.
    Favuzza P, Blaser S, Dreyer AM, Riccio G, Tamborrini M, Thoma R, Matile H, Pluschke G.
    Malar J; 2016 Mar 15; 15():161. PubMed ID: 26979066
    [Abstract] [Full Text] [Related]

  • 6. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S, Faber BW, Kocken CHM, Remarque EJ.
    BMC Immunol; 2019 Jul 30; 20(1):25. PubMed ID: 31362695
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB, Durier C, Kara L, Houard S, Gansane A, Loulergue P, Bahuaud M, Benhamouda N, Nebié I, Faber B, Remarque E, Launay O, AMA1-DiCo Study Group.
    Vaccine; 2017 Oct 27; 35(45):6218-6227. PubMed ID: 28947345
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine.
    Pourhashem Z, Nourani L, Sani JJ, Yousefi H, Pirahmadi S, Sabouri M, Raz A, Djadid ND, Zakeri S, Mehrizi AA.
    Malar J; 2023 Dec 09; 22(1):374. PubMed ID: 38071314
    [Abstract] [Full Text] [Related]

  • 9. Process development and preclinical evaluation of a major Plasmodium falciparum blood stage vaccine candidate, Cysteine-Rich Protective Antigen (CyRPA).
    Somanathan A, Mian SY, Chaddha K, Uchoi S, Bharti PK, Tandon R, Gaur D, Chauhan VS.
    Front Immunol; 2022 Dec 09; 13():1005332. PubMed ID: 36211427
    [Abstract] [Full Text] [Related]

  • 10. Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A.
    Geiger KM, Guignard D, Yang C, Bikorimana JP, Correia BE, Houard S, Mkindi C, Daubenberger CA, Spertini F, Corradin G, Audran R.
    Front Immunol; 2020 Dec 09; 11():412. PubMed ID: 32210975
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S, Jafarshad A, Servis C, Frank G, Reed S, Pink R, Druilhe P, Spertini F, Corradin G.
    Vaccine; 2016 Mar 18; 34(13):1566-1574. PubMed ID: 26874325
    [Abstract] [Full Text] [Related]

  • 13. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
    Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG, Ockenhouse CF, Spring MD.
    Malar J; 2013 Jan 23; 12():29. PubMed ID: 23342996
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV, Biswas S, Pillai CR, Saxena RK.
    Vaccine; 2008 Aug 18; 26(35):4526-35. PubMed ID: 18590786
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.
    Malar J; 2011 Dec 13; 10():359. PubMed ID: 22166048
    [Abstract] [Full Text] [Related]

  • 16. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
    Sirima SB, Richert L, Chêne A, Konate AT, Campion C, Dechavanne S, Semblat JP, Benhamouda N, Bahuaud M, Loulergue P, Ouédraogo A, Nébié I, Kabore M, Kargougou D, Barry A, Ouattara SM, Boilet V, Allais F, Roguet G, Havelange N, Lopez-Perez E, Kuppers A, Konaté E, Roussillon C, Kanté M, Belarbi L, Diarra A, Henry N, Soulama I, Ouédraogo A, Esperou H, Leroy O, Batteux F, Tartour E, Viebig NK, Thiebaut R, Launay O, Gamain B.
    Lancet Infect Dis; 2020 May 13; 20(5):585-597. PubMed ID: 32032566
    [Abstract] [Full Text] [Related]

  • 17. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S, Zakeri S, A Mehrizi A, D Djadid N, Raz AA, J Sani J, Abbasi R, Ghorbanzadeh Z.
    Malar J; 2019 Apr 24; 18(1):146. PubMed ID: 31014347
    [Abstract] [Full Text] [Related]

  • 18. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohmmed A, Chauhan VS.
    Infect Immun; 2010 Feb 24; 78(2):872-83. PubMed ID: 19933832
    [Abstract] [Full Text] [Related]

  • 19. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
    Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.
    J Immunol; 2010 Dec 15; 185(12):7583-95. PubMed ID: 21098232
    [Abstract] [Full Text] [Related]

  • 20. First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.
    Mordmüller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, Smedegaard HH, Ditlev SB, Soegaard M, Poulsen L, Dyring C, Calle CL, Knoblich A, Ibáñez J, Esen M, Deloron P, Ndam N, Issifou S, Houard S, Howard RF, Reed SG, Leroy O, Luty AJF, Theander TG, Kremsner PG, Salanti A, Nielsen MA.
    Clin Infect Dis; 2019 Oct 15; 69(9):1509-1516. PubMed ID: 30629148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.